Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRT 2584 XX dose-escalation placebo-controlled phase 2 trial in relapsing multiple sclerosis
2005-005985-35Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BIRT 2584 XX in multiple sclerosis (MS) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Cumulative number of newly active unique lesions on MRI. Started Jul 2006; status: completed.
02
Drugs
BIRT 2584 XX
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2005-005985-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005985-35.